Saturday, March 2, 2024

CATEGORY

Daiichi Sankyo

Priority Review Granted in the US for Enhertu in Metastatic HER2-Positive Solid Tumors

AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for...

FDA Awards Priority Review to Daiichi Sankyo-Merck’s Treatment for Lung Cancer

The US FDA has given priority review to Daiichi Sankyo and Merck’s application for patritumab deruxtecan, a potential therapy for non-small cell lung cancer...

AstraZeneca and Daiichi Sankyo’s Datopotamab Deruxtecan Shows Promise in Lung Cancer Trial

AstraZeneca and Daiichi Sankyo have achieved significant progress in the fight against non-small cell lung cancer (NSCLC). Their jointly developed antibody-drug conjugate (ADC), datopotamab...

AstraZeneca and Daiichi Sankyo’s Enhertu Approved in EU for Advanced Non-Small Cell Lung Cancer

AstraZeneca and Daiichi Sankyo have received approval from the European Commission for Enhertu, a targeted treatment for adult patients with advanced non-small cell lung...

Latest news

Sticky Image